Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom

Lindsay Claxton,; Robert Hodgson; William Malcom; Ruth Jacob; Matthew Taylor

doi:10.1007/s40273-016-0459-z

Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom

Lindsay Claxton,^*, Robert Hodgson, William Malcom, Ruth Jacob, Matthew Taylor

^*Corresponding author for this work

Centre for Reviews and Dissemination

Research output: Contribution to journal › Article › peer-review

Abstract

Previously developed models in ophthalmology have generally used a Markovian structure. There are a number of limitations with this approach, most notably the ability to base patient outcomes on best-corrected visual acuity (BCVA) in both eyes, which may be overcome using a different modelling structure. Simulation modelling allows for this to be modelled more precisely, and therefore may provide more accurate and relevant estimates of the cost effectiveness of ophthalmology interventions.

Original language	English
Pages (from-to)	1-12
Number of pages	13
Journal	PharmacoEconomics
Early online date	27 Oct 2016
DOIs	https://doi.org/10.1007/s40273-016-0459-z
Publication status	Published - Oct 2016

Bibliographical note

This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details

Access to Document

10.1007/s40273-016-0459-z

Simulation Modelling in Ophthalmology final version
This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details (embargo period: 12 months)
Accepted author manuscript, 578 KB

Cite this

@article{c96e98d7d4ee4178b2789c6a11c23234,

title = "Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom",

abstract = "Previously developed models in ophthalmology have generally used a Markovian structure. There are a number of limitations with this approach, most notably the ability to base patient outcomes on best-corrected visual acuity (BCVA) in both eyes, which may be overcome using a different modelling structure. Simulation modelling allows for this to be modelled more precisely, and therefore may provide more accurate and relevant estimates of the cost effectiveness of ophthalmology interventions.",

author = "Lindsay Claxton, and Robert Hodgson and William Malcom and Ruth Jacob and Matthew Taylor",

note = "This is an author-produced version of the published paper. Uploaded in accordance with the publisher{\textquoteright}s self-archiving policy. Further copying may not be permitted; contact the publisher for details ",

year = "2016",

month = oct,

doi = "10.1007/s40273-016-0459-z",

language = "English",

pages = "1--12",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Simulation Modelling in Ophthalmology

T2 - Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom

AU - Claxton,, Lindsay

AU - Hodgson, Robert

AU - Malcom, William

AU - Jacob, Ruth

AU - Taylor, Matthew

N1 - This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details

PY - 2016/10

Y1 - 2016/10

N2 - Previously developed models in ophthalmology have generally used a Markovian structure. There are a number of limitations with this approach, most notably the ability to base patient outcomes on best-corrected visual acuity (BCVA) in both eyes, which may be overcome using a different modelling structure. Simulation modelling allows for this to be modelled more precisely, and therefore may provide more accurate and relevant estimates of the cost effectiveness of ophthalmology interventions.

AB - Previously developed models in ophthalmology have generally used a Markovian structure. There are a number of limitations with this approach, most notably the ability to base patient outcomes on best-corrected visual acuity (BCVA) in both eyes, which may be overcome using a different modelling structure. Simulation modelling allows for this to be modelled more precisely, and therefore may provide more accurate and relevant estimates of the cost effectiveness of ophthalmology interventions.

U2 - 10.1007/s40273-016-0459-z

DO - 10.1007/s40273-016-0459-z

M3 - Article

SN - 1170-7690

SP - 1

EP - 12

JO - PharmacoEconomics

JF - PharmacoEconomics

ER -